GENMAB A/S's ticker is GMAB and the CUSIP is 372303206. A total of 191 filers reported holding GENMAB A/S in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,718,920 | +70.5% | 48,744 | +83.7% | 0.00% | +50.0% |
| Q2 2023 | $1,008,307 | -1.9% | 26,531 | -2.6% | 0.00% | 0.0% |
| Q1 2023 | $1,028,273 | -24.4% | 27,229 | -15.3% | 0.00% | -33.3% |
| Q4 2022 | $1,360,930 | +79.3% | 32,135 | +36.0% | 0.00% | +50.0% |
| Q3 2022 | $759,000 | +33.4% | 23,624 | +34.9% | 0.00% | +100.0% |
| Q2 2022 | $569,000 | -58.7% | 17,518 | +20.8% | 0.00% | -66.7% |
| Q1 2022 | $1,379,000 | +111.8% | 14,499 | -11.9% | 0.00% | +200.0% |
| Q4 2021 | $651,000 | -16.8% | 16,461 | -8.0% | 0.00% | -50.0% |
| Q3 2021 | $782,000 | +34.1% | 17,895 | +25.7% | 0.00% | +100.0% |
| Q2 2021 | $583,000 | -30.8% | 14,239 | -44.5% | 0.00% | -50.0% |
| Q1 2021 | $842,000 | -31.7% | 25,654 | -15.3% | 0.00% | -33.3% |
| Q4 2020 | $1,232,000 | +28.3% | 30,283 | +15.2% | 0.00% | 0.0% |
| Q3 2020 | $960,000 | +59.2% | 26,282 | +47.8% | 0.00% | +50.0% |
| Q2 2020 | $603,000 | +137.4% | 17,783 | +48.2% | 0.00% | +100.0% |
| Q1 2020 | $254,000 | – | 12,001 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 242,848 | $9,169,940 | 3.80% |
| Capricorn Fund Managers Ltd | 110,643 | $4,177,880 | 1.28% |
| Arlington Capital Management, Inc. | 35,591 | $1,343,916 | 1.26% |
| XY Capital Ltd | 76,884 | $2,903,140 | 1.13% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 88,000 | $3,322,880 | 0.93% |
| TORRAY INVESTMENT PARTNERS LLC | 110,807 | $4,184,072 | 0.75% |
| Hardman Johnston Global Advisors LLC | 585,139 | $22,094,849 | 0.72% |
| Yorktown Management & Research Co Inc | 16,600 | $626,816 | 0.68% |
| First Light Asset Management, LLC | 160,025 | $6,042,544 | 0.54% |
| MIRABELLA FINANCIAL SERVICES LLP | 28,260 | $2,505,855 | 0.38% |